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1 |  INTRODUCTION
The most common cause of genetic homocystinuria is cysta-
thionine beta-synthase (CBS) deficiency or classical homo-
cystinuria (HCU) (OMIM #236200), which is an autosomal 
recessive disease caused by biallelic pathogenic variations in 
CBS gene. There are also other 13 genes related to monogenic 
homocystinurias like MTHFR, MMACHC, and MMADHC. 
HCU is biochemically characterized by the accumulation of 
homocysteine (Hcy) and methionine (Met) and by decreased 
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Abstract
Background: Biallelic pathogenic variants in CBS gene cause the most common 
form of homocystinuria, the classical homocystinuria (HCU). The worldwide preva-
lence of HCU is estimated to be 0.82:100,000 [95% CI, 0.39–1.73:100,000] accord-
ing to clinical records and 1.09:100,000 [95% CI, 0.34–3.55:100,000] by neonatal 
screening. In this study, we aimed to estimate the minimal worldwide incidence of 
HCU.
Methods: The 25 most common pathogenic alleles of HCU were identified through 
a literature review. The incidence of HCU was estimated based on the frequency of 
these common pathogenic alleles in a large genomic database (gnomAD).
Results: The minimum worldwide incidence of HCU was estimated to be 
~0.38:100,000, and the incidence was higher in Europeans non-Finnish 
(~0.72:100,000) and Latin Americans (~0.45:100,000) and lower in Africans 
(~0.20:100,000) and Asians (~0.02:100,000).
Conclusion: Our data are in accordance with the only published metanalysis on this 
topic. To our surprise, the observed incidence of HCU in Europeans was much lower 
than those described in articles exploring small populations from northern Europe 
but was similar to the incidence described on the basis of neonatal screening pro-
grams. In our opinion, this large dataset analyzed and its population coverage gave 
us greater precision in the estimation of incidence.
K E Y W O R D S
classical homocystinuria, frequent pathogenic variants, genomic databases, homocysteine, incidence
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cysteine levels. The main clinical complications in untreated 
HCU patients are found in the eyes, skeleton, central nervous 
system, and vascular system (Morris et al., 2017).
More than 200 pathogenic variants have been described 
in the CBS gene, and most of these are rare and private vari-
ants (Stenson et al., 2017). However, the four most preva-
lent mutations (p.Ile278Thr, p.Thr191Met, p.Gly307Ser, 
and p.Trp323Ter) represent half of all HCU alleles reported 
worldwide (Kraus, 2019). Rare metabolic monogenic dis-
eases like HCU are usually characterized by allelic hetero-
geneity and show a broad spectrum of clinical expressivity 
(e.g., for some diseases, even the penetrance is not 100%). 
Besides that, in the absence of newborn screening programs, 
their diagnosis is usually delayed. Those factors together con-
tribute for making the estimating of the incidence/prevalence 
of those diseases a real challenge. In the case of HCU, this is 
even more complicated, since there is not a good biomarker 
for newborn screening of the milder forms (the “responsive 
to pyridoxine” patients).
The worldwide prevalence of HCU based on the num-
ber of known patients is estimated to be between 0.29 and 
1:100,000 individuals (Moorthie, Cameron, Sagoo, Bonham, 
& Burton, 2014; S.H., H.L., & J.P., 2001). Moorthie et al., 
2014 performed a systematic review and meta-analysis to es-
timate the prevalence of HCU and found a worldwide prev-
alence based on diagnosis of symptomatic individuals of 
0.82:100,000 [95% CI, 0.39–1.73:100,000], while that based 
on neonatal screening by MS/MS was 1.01:100,000 [95% CI, 
0.34–3.55:100,000] newborns (NBs). We like to point out 
that the study of Moorthie et al., 2014 included the Qatari 
population, with an extremely high prevalence of HCU of 
55:100,000 which may introduce an overestimation of the 
worldwide prevalence.
Another strategy to estimate the incidence of HCU is via 
determining the frequency of carriers for pathogenic alleles in 
the CBS gene and next use it to calculate the expected number 
of patients with HCU via the Hardy–Weinberg (HW) equation. 
The first researchers to use this approach were Gaustadnes, 
Ingerslev, & Rütiger, 1999, who screened 500 consecutive 
Danish NBs for the c.833T>C mutation and estimated the 
incidence of HCU to be at least 4.8:100,000. Linnebank et al., 
2001 also conducted screening for the c.833T>C mutation in 
200 healthy unrelated German controls and calculated the fre-
quency of homozygosity for this mutation to be 5.6:100,000 
individuals. In Norway, Refsum, Fredriksen, Meyer, Ueland, 
& Kase, 2004 determined the presence of six specific muta-
tions of the CBS gene in 1,133 NB blood samples randomly 
selected from ~12,000 samples, and they calculated an HCU 
prevalence of ~15.6:100,000. Janosík et al., 2009 estimated 
the frequency of HCU in the Czech Republic via determining 
the presence of the c.1105C>T mutation in 600 NB blood 
spots, and they calculated the birth prevalence for HCU to be 
at least 2.5:100,000.
Thus, there is an about a 6-fold unexplained discrepancy 
between the number of known patients with HCU and that 
calculated on the basis of the number of carriers detected via 
genetic analyses of relatively small populations in Northwest 
Europe. There is no clear explanation for this discrepancy, 
but it could be due to the low penetrance or expressivity of 
some genotypes or to underdiagnoses. This discrepancy trig-
gered us to obtain a more reliable estimate of the minimal 
worldwide incidence of HCU, using the data available in rel-
evant large genomic databases.
2 |  METHODS
We determined the 25 most common pathogenic variants 
in HCU patients via a literature review using the key terms 
“CBS mutation” and “Classical homocystinuria” in PubMed 
(www.ncbi.nlm.nih.gov/pubmed) and by examining refer-
ences cited in related papers. Publications that contained 
molecular data in HCU patients were selected and used in 
the analysis, the search resulted in the inclusion of forty pa-
pers, containing 1,026 independent alleles from 25 countries. 
Since several of these studies described only a few patients, 
which could lead to overestimation of the frequency of a spe-
cific allele, only data from those countries in which at least 
ten alleles (five non-related patients) were used in the analy-
ses totaling 1,014 alleles (Table 1).
Based on the 25 most frequent variants of the literature 
review, we conducted searches to determine the prevalence 
of these variants in the general population in two relevant ge-
nomic databases: gnomAD v2.1.1 (Lek et al., 2016, last ac-
cessed October 2019) and ABraOM (Naslavsky et al., 2017, 
last accessed July 2019). The first database includes world-
wide data from 141,456 unrelated individuals sequenced 
as part of various disease-specific and population genetic 
studies and it is possible to access different subgroups in 
which individuals can overlap (e.g., one individual could be 
included in more than one subgroup): controls, non-cancer, 
non-neuro, and non-TOPMed. The individuals are clustered 
according to their genetic determination of ancestry. For 
example, individuals residing in the USA or Brazil may be 
clustered as European, African or Asian according to their 
genetic background. The second database, ABraOM, uses 
data from 609 healthy elderly individuals who were selected 
using a standardized sampling process from the city of São 
Paulo, Brazil; nearly 10% of the Brazilian population is lo-
cated in this city, making it reasonably representative of the 
country.
The estimated incidence of HCU was calculated based 
on the assumption that HW equilibrium exists; thus, the fre-
quencies are ‘‘p’’ for the wild-type allele and ‘‘q’’ for the 
pathogenic allele. The different allele frequencies for each 
pathogenic variant were summed.
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3 |  RESULTS
HCU patients from all selected studies were grouped accord-
ing to their country of origin, and allelic frequencies were 
calculated for each variant in each country. The 25 most fre-
quent variants of the CBS gene are described in Table 1.
3.1 | Most common variants
The five most common pathogenic CBS variants identified 
in our literature review (46% of alleles) were p.Arg336Cys, 
p.Ile278Thr, p.Gly307Ser, p.Thr191Met, and p.Trp323Ter. 
The countries where these pathogenic variants are most com-
mon are highlighted in Figure 1 and Table 1.
3.2 | p.Arg336Cys
In this study, p.Arg336Cys presented an overall allele fre-
quency among HCU patients of 14% (149 alleles), and it was 
by far the most common variant in Qatar (97% of alleles). 
p.Arg336Cys was found in 15% of HCU Saudi Arabian pa-
tients but in no more than 10% of cases in European and Asian 
patients.
In the gnomAD, this variant was found only in non-Finn-
ish Europeans, and it was present in 0.004% of alleles in 
this population. Patients homozygous for p.Arg336Cys are 
usually unresponsive to treatment with pyridoxine, and un-
treated patients present a severe clinical phenotype with 
involvement of the eyes, bones and vascular and central ner-
vous systems.
3.3 | p.Ile278Thr
Our data showed an allele frequency among HCU patients 
of 13% (133 alleles) for p.Ile278Thr, which is the most 
widely dispersed variant in the world. The p.Ile278Thr 
was the most common pathogenic variant reported in the 
USA, Brazil, France, Italy, Germany, the Netherlands, the 
Czech Republic, Slovakia, Poland, Denmark, England, 
and Israel. Figure 2 illustrates the presence and frequency 
of this pathogenic variant around the world in HCU 
patients.
According to gnomAD, this variant was found in 
non-Finnish Europeans (0.143% of alleles were pathogenic), 
Finnish Europeans (0.057%), and Africans (0.023%), but it 
was not present in Asian or Latin American individuals; how-
ever, it was present in almost 1% of alleles in the Brazilian 
F I G U R E  1  Most common pathogenic alleles of the CBS gene per country: p.Ile278Thr, p.Thr191Met, p.Gly307Ser, Trp323Ter, and 
p.Arg336Cys. The most prevalent variant in the world (p.Ile278Thr) is the most common in The Netherlands (allelic frequency: 55%), Poland 
(36%), Germany (33%), England (29%), Italy (29%), Denmark (20%), Czech Republic and Slovakia (20%), USA (19%), Israel (18%), France 
(17%), and Brazil (16%). The variant p.Thr191Met is the most common in Colombia (73%), Spain (44%), Portugal (23%), and Venezuela (20%). In 
Ireland (66%) and Australia (22%) the most common variant is p.Gly307Ser. The variant Trp323Term is the most common in Saudi Arabia (77%), 
and in Qatar (highlighted by the red circle) the most common variant is p.Arg336Cys (97%). Other prevalent mutations are c.700_702delGAC in 
Korea (20%), c.1224-2A>C in Russia (27%), p.Arg121His and p.Lys441Ter in Japan (16% each one), p.Arg125Gln in China (15%), in Argentina 
p.Ala226Thr (22%) and in Norway p.Arg266Lys (34%)
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sample studied in ABraOM. Patients homozygous for p.Ile-
278Thr are usually responsive to treatment with pyridoxine 
and present a mild to moderate phenotype.
3.4 | p.Gly307Ser
A reported allele frequency of 10% (108 alleles) was found for 
p.Gly307Ser in HCU patients from the USA, Europe, Israel, 
Australia, and Qatar. p.Gly307Ser was the most common re-
ported pathogenic variant in Ireland (66%) and Australia (22%).
According to gnomAD this pathogenic allele was present 
in Europeans (0.03% of all alleles) and Africans (0.008%) 
(Table 2). Patients homozygous for p.Gly307Ser are usually 
non-responsive to treatment with pyridoxine and present a 
severe clinical phenotype.
3.5 | p.Thr191Met
p.Thr191Met presented an allele frequency among HCU patients 
of 8% (82 alleles) and was the most common pathogenic variant 
reported in countries of the Iberian Peninsula and in their for-
mer colonies in Latin America. The highest frequencies of this 
variant among HCU patients were found in Spain (44% of the 
alleles), Portugal (23%), Colombia (73%), and Venezuela (20%).
Data from gnomAD indicated the presence of the vari-
ant in Latin Americans (0.038%), but it was not identified 
in ABraOM. Patients who are p.Thr191Met homozygous are 
usually non-responsive to pyridoxine and present a moderate 
to severe clinical phenotype.
3.6 | p.Trp323Ter
The overall allele frequency among HCU patients of 
p.Trp323Ter was 2% (25 alleles). This variant was reported 
in patients from Saudi Arabia (77% of alleles) and northeast 
Brazil (6% of alleles). Interestingly, according to gnomAD data 
this variant is very rare and found only in one allele among 
Asians. This variant was not observed in ABraOM, which ana-
lyzed persons from São Paulo, Brazil. Patients homozygous 
for p.Trp323Ter are usually non-responsive to treatment with 
pyridoxine and present a moderate to severe clinical phenotype.
3.7 | HCU worldwide incidence
In the genetic database gnomAD, we found 304 individuals 
who were carriers for any of 20 of the 25 most frequent path-
ogenic alleles of the CBS gene, yielding an estimated HCU 
incidence (i.e., homozygosity or compound heterozygosity) 
of ~0.38:100,000 (95% CI, 0.29–0.39:100,000) individuals. 
When we analyzed only the control group of gnomAD, the 
estimated incidence was ~0.22:100,000; if we analyze only 
the non-neuro subgroup the incidence is ~0.42:100,000 in 
(Table 2). No homozygous individuals, for the 25 most fre-
quent pathogenic variants, were found in this database.
Analyzing the data according to different ancestry, we 
calculated an HCU incidence of ~0.72:100,000 individuals 
among Europeans (non-Finnish), ~0.45:100,000 individ-
uals among Latin Americans, ~0.20:100,000 individuals 
among Africans and ~0.02:100,000 individuals in Asians 
(Table 2).
F I G U R E  2  Distribution of the p.Ile278Thr variant among Classical Homocystinuria patients. Presence of the pathogenic variant in countries 
with at least 10 pathogenic alleles of HCU described in the literature. Countries without at least 10 published HCU alleles, or with no HCU patients 
genotyped, are presented in white. Gray indicates countries in which the variant p.Ile278Thr was not described among HCU patients
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3.8 | HCU incidence in southeastern Brazil
In the ABraOM database, we found only two of the 25 variants 
analyzed (p.Ile278Thr and p.Ala114Val). A total of 12 individu-
als carrying either of the pathogenic variants were included in this 
database (11 carriers of p.Ile278Thr and one of p.Ala114Val), 
yielding an estimated incidence of HCU of ~9.7:100,000 indi-
viduals. No homozygous individuals were found.
4 |  DISCUSSION
Knowledge of the genetic background of HCU in different 
populations is generally poor and even contradictory. This 
omission hampers proper patient genetic counseling and ap-
propriate genetic testing. Knowledge of the prevalent path-
ogenic variants and their frequencies will support decision 
making within national screening programs. Furthermore, 
there is an approximately 6-fold discrepancy between the 
number of known patients with HCU and the estimate cal-
culated on the basis of the number of heterozygotes de-
tected via genetic analyses of relatively small populations.
In this study, we used the results of published articles 
to characterize the worldwide mutational profiles of HCU 
patients. Next, we used the 25 most common published 
pathogenic variants (Table 1) to determine the correspond-
ing allele frequencies in genomic databases and to calculate 
the incidence of HCU in different ancestralities (Table  2). 
Interestingly, the frequencies of these 25 most commonly 
pathogenic variants reported in various countries are in 
line with the data from genomic databases; for instance, 
p.Ile278Thr was very common in different ancestries, 
p.Thr257Met and p.Ala114Val were described in patients 
with HCU in different continents and found in several an-
cestralities and p.Thr191Met was found in Latin Americans. 
Europeans seems to be the group with the greatest allelic di-
versity, which leads us to hypothesize that dispersion of these 
pathogenic alleles occurred during the colonization period of 
America and Africa. In addition to the much lower incidence 
of HCU, we observed a distinct pattern of mutations in Asia 
and Russia, where 75% of alleles differ from the 10 most 
common pathogenic variants worldwide.
Based on biochemical neonatal screening data obtained 
by the measurement of Met in dried blood spots (DBSs), 
Naughten, Yap, & Mayne, 1998 reported HCU incidences 
of 0.77:100,000 NBs in Germany, 0.8:100,000 NBs in 
England and 0.34:100,000 NBs in the USA and higher inci-
dences of 1.5:100,000 NBs in Ireland and 1.8:100,000 NBs 
in Italy. According to Mathias & Bickel, 1986, the incidence 
in Germany was 0.32:100,000 NBs based on biochemical 
neonatal screening data of almost 1 million individuals. 
Biochemical neonatal screening of 820,797 individuals in 
New South Wales, Australia, around the 1960s revealed 14 
cases of HCU, resulting in an incidence of 1.72:100,000 NBs 
(Wilcken & Turner, 1978).
In Asian countries, a much lower HCU incidence is ob-
served. In Japan, an extremely low incidence of 0.11:100,000 
NBs was observed despite an effective biochemical screening 
program (Naughten et al., 1998). National biochemical neo-
natal screening performed in the Philippines between 1996 
and 2001 identified no HCU patients among 176,548 sam-
ples (Padilla, 2003). In Taiwan, 5 million individuals were 
subjected to biochemical neonatal screening for HCU, and 
only 3 were diagnosed with the disease. In sharp contrast, 
an extremely high frequency of HCU of 416:100,000 indi-
viduals was found on an island inhabited by an Austronesian 
Taiwanese Tao tribe (Lu et al., 2012). Kaur, Das, & Verma, 
1994 investigated 2,560 high-risk patients with strong suspi-
cion of an inborn error of metabolism in northern India, and 
the most commonly found disorder was HCU (0.6%).
Qatar is the country with the highest incidence of HCU in 
the world due to a founder effect of p.Arg336Cys. This patho-
genic variant rate is very frequent in three tribes of the Qatari 
population, and consanguineous marriages even enhance the 
high incidence of HCU. Initially the incidence of HCU was 
estimated to be ~33:100,000 individuals (El-Said et al., 2006). 
However, after the implementation of neonatal screening 
through the detection of tHcy and Met combined with genetic 
screening, the estimated incidence of HCU in the Qatari popu-
lation increased to 55:100,000 NBs (Gan-Schreier et al., 2010).
Newborn screening is being carried out in countries with 
high incidences of HCU, such as Ireland and Qatar (Yap & 
Naughten, 1998; Zschocke et al., 2009). For this purpose, 
tHcy is measured in DBSs with a dedicated method in Qatar. 
However, all other newborn screening programs measure 
Met in DBSs, which results in a high proportion of false neg-
atives, particularly for pyridoxine-responsive forms of HCU, 
because these patients seem not to develop hypermethionin-
emia in the first days of life, so due to the limitation of new-
born screening method this patients are likely not diagnosed 
(Bowron, Barton, Scott, & Stansbie, 2005; McHugh et al., 
2011; Peterschmitt, Simmons, & Levy, 1999). Countries in 
Latin America have no neonatal screening program for HCU; 
however, based on our estimation of HCU incidences in these 
populations of ~0.45:100,000 we like to advocate to intro-
duce newborn screening for HCU in Latin American coun-
tries. Countries such as Japan and the USA have neonatal 
screening programs for HCU, even though the incidences in 
these countries are lower than (Japan) or similar to (USA) 
those estimated in Latin America.
Among CBS mutations, p.Ile278Thr is geographically the 
most widespread. Studying the emergence and dispersal of this 
mutation, Vyletal et al., 2007 reported that haplotype c. [833C; 
844_845ins68] is very common in sub-Saharan Africa (up to 40% 
of control chromosomes), less frequent throughout Europe and 
America (5%–10% of control chromosomes), and rare in Asia 
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(0.16%–2.5% of control chromosomes). It was concluded that 
the p.Ile278Thr variant occurred repeatedly and independently 
in the recent history of the European population. Interestingly 
and confusing is the haplotype c.[833C; 844_845ins68] on the 
CBS gene, which contains the c.833T>C. But this haplotype 
is considered non-pathogenic since c.844_845ins68 creates an 
alternative splice site that rescues the wildtype CBS sequence 
from the mutated allele, resulting in normal CBS enzyme ac-
tivity and normal Hcy concentrations (Kluijtmans et al., 1997). 
We have to take into account that in the Brazilian database the 
presence of variant c.844_845ins68 has not been described, 
but since the frequency of p.Ile278Thr is very high (0.9%), 
we cannot rule out the possibility that some of these individu-
als may carry the non-pathogenic haplotype. In the gnomAD, 
we assumed that the individuals heterozygous for p.Ile278Thr 
(0.08% of the total sample) had the isolated pathogenic vari-
ant, since the frequency of individuals with the c.844_845ins68 
variant was approximately 12%.
The prevalence of HCU varies dramatically between re-
gions from 416:100,000 on Orchid Island and 55:100,000 
in Qatar to less than one in one million in the Taiwanese 
Han population (Gan-Schreier et al., 2010; Lu et al., 2012). 
In this study, we used the genetic database gnomAD to de-
termine the frequency of CBS heterozygotes and next cal-
culated the worldwide incidence of HCU, which was found 
to be approximately 0.38:100,000 individuals. Stratifying 
populations by ancestry, the highest incidence of HCU was 
found in Europeans and Latin Americans. A much lower in-
cidence was found in Asians. The incidences in these various 
regions were more or less in line with those found through 
neonatal biochemical screening. For instance, in Europeans, 
an incidence of 0.72:100,000 individuals was calculated on 
the basis of the number of heterozygotes in gnomAD ver-
sus 0.77:100,000 according to neonatal screening, and in 
Asian, the corresponding values were 0.02:100,000 versus 
0.07:100,000 individuals (Naughten et al., 1998).
Another remarkable finding is that the incidence cal-
culated in this study for Europeans of approximately 
~0.72:100,000 individuals is much lower (approximately 
6 to 7 times) than those described in four different studies. 
At least 4.8:100,000 live births in Denmark, 5.6:100,000 in 
Germany, 2.5:100,000 in Czech Republic ~15.6:100,000 in 
Norway. We have no explanation for this discrepancy except 
that the numbers of studied individuals were relatively small 
(200 to maximal 1,133 individuals) and that publication bias 
may have played a role. The Europeans sample size of gno-
mAD is approximately 115 times larger than the sample sizes 
of these studies and should therefore provide a much more 
precise incidence rate.
We estimated the number of HCU patients using HW 
equilibrium. The HW principle presents limitations because it 
analyzes allele frequencies and genotype counts in successive 
generations and predicts that in a random mating population 
of infinite size, allele and genotype frequencies should re-
main constant from one generation to the next. Factors that 
may disrupt the HW equilibrium included mutation rate, nat-
ural selection, migration, population structure (nonrandom 
marriage and/or consanguinity) and nonrandom selection of 
the samples studied (Piel et al., 2016; Waples, 2015). Overall, 
we assume that these limitations do not substantially affect 
the numbers we calculated.
The genomic database gnomAD consists of 282,912 al-
leles and includes data from consortia such as 1,000 genomes, 
GO-ESP and TOPMed and provides sequence data from un-
related individuals from various disease-specific populations 
included in genetic studies. Therefore, our frequency analysis 
is based on diverse populations from various countries and 
ethnicities clustered according to their genetic determination 
of ancestry. Although the calculated frequency of HCU is rel-
atively low, we consider it to be rather precise estimation of 
incidence because of the large number of individuals and the 
different genetic backgrounds included.
Genetic data provided by databases present limitations be-
cause of the heterogeneous inclusion criteria of the original 
studies such as age or selection based on diseases. Although 
gnomAD is the largest public genetic database to our knowl-
edge, it should be taken into account that individuals in this 
database are clustered according to their genetically deter-
mined ancestry and not according to the country or continent 
where they reside. Approximately 45% of individuals are 
classified as exhibiting European ancestry, so gnomAD only 
partially reflects global genetic diversity.
Another possible limitation of this study was the method 
used to define the 25 most common pathogenic variants 
among HCU patients. We have considered studying all 
variants described in the CBS gene in the gnomAD popula-
tion, but the filtering of truly pathogenic variants is rather 
poor and inaccurate, and we kept in mind that the low pen-
etrance or expressivity of some genotypes, could lead to a 
falsely increased incidence result. So, an extensive review 
of the literature was performed to identify the most com-
mon pathogenic variants in HCU patients, but some rela-
tively common variants may still have been missed. Each 
study presents its own methodology for the inclusion and 
diagnosis of patients. In many countries, indicated in white 
in Figure 1, there are no reported HCU patients. No alleles 
were found in the genomic databases for five of the twen-
ty-five pathogenic variants analyzed (p.Leu101Pro, p.Cy-
s165Tyr, p.Ala226Thr, p.Lys441Ter, and p.Lys523Serfs). 
Our study included three pathogenic variants that are known 
to be responsive to pyridoxine (p.Arg266Lys, p.Ala226Thr, 
and p.Ile278Thr), which accounted for an important per-
centage of the alleles present in this population (~20%). 
Pyridoxine-responsive patients are known to present with a 
milder clinical phenotype and presenting later in life or may 
even have no symptoms at all.
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When analyzing the total population of gnomAD we 
found an estimated incidence of HCU of 0.38:100,000 indi-
viduals. In addition, we also analyzed the subgroups of indi-
viduals classified as non-neuro and controls, and calculated 
for them the incidence of HCU of 0.42 and 0.22:100,000, 
respectively. Although the incidence estimations are not ex-
actly the same, it remains more or less similar to those found 
in neonatal screening and much lower than the incidence re-
ported in other studies with heterozygous analysis.
The genetic database ABraOM consists of 1,218 alleles 
from individuals living in São Paulo, Brazil, and 12 pathogenic 
alleles were found in this database. This number resulted in 
a calculated incidence of HCU of ~9.7:100,000 individuals, 
which is more in line with the incidence found in the small 
European studies. If ABraOM is representative of the Southeast 
Region of Brazil, this result may indicate that many patients are 
not being diagnosed. However, the relatively small sample size 
may affect the results. Among the CBS mutations reported in 
Brazilian HCU patients, the variant p.Ile278Thr was the most 
common (18%) (Poloni et al., 2018). In our search in the ge-
nomic database ABraOM, p.Ile278Thr was the most common 
variant with a striking frequency of 0.00903. It may well be 
possible that also the haplotype c.[833C; 844_845ins68] was 
ranked as p.Ile278Thr and so may have resulted in an overesti-
mation of the number of HCU patients.
Since HCU is a treatable disease and given the severe clin-
ical complications of HCU, such as thromboembolic events, 
dislocation of the lens and neurological complications, the 
early recognition of HCU patients by health professionals is 
extremely relevant. The results presented in this study based 
on the number of heterozygotes for CBS pathogenic variants 
in a large genomic database reinforce efforts to recognize 
CBS patients and to implement effective newborn screening 
methods, particularly in regions with high incidences.
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